Grundläggande statistik
| LEI | 2138001K2FX6SHK2B339 |
| CIK | 1639691 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to LivaNova PLC
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2025 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 6, 2025 |
LivaNova Reports Second-Quarter 2025 Results; Raises 2025 Guidance EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Second-Quarter 2025 Results; Raises 2025 Guidance –Delivered double-digit reported and organic revenue growth and continued operating margin expansion –Raised full-year 2025 revenue, adjusted earnings per share, and adjusted free cash flow guidance(1) –Initiated process with U.S. Centers for Medicare and Medicaid Services for reconsideration of national c |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37599 LivaNova |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 13, 2025 |
Calculation of Filing Fee Tables S-8 LivaNova PLC Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Ordinary Shares, 1. |
|
| June 13, 2025 |
As filed with the Securities and Exchange Commission on June 12, 2025. As filed with the Securities and Exchange Commission on June 12, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LivaNova PLC (Exact name of Registrant as specified in its charter) England and Wales 98-1268150 (State or other jurisdiction of incorporation or organization) (I.R.S. Em |
|
| June 11, 2025 |
IMPORTANT NOTICES European Union/European Economic Area (“EU/EEA”) In relation to each Member State of the EEA, an offer to the public of any securities that comprise the SARs (as defined below) (together “Securities”) which are the subject of the offer contemplated by this Grant Notice (as defined below) may not be made in that Member State, except that an offer to the public in that Member State |
|
| June 11, 2025 |
IMPORTANT NOTICES European Union/European Economic Area (“EU/EEA”) In relation to each Member State of the EEA, an offer to the public of any securities that comprise the PSUs (as defined below) (together “Securities”) which are the subject of the offer contemplated by this Grant Notice (as defined below) may not be made in that Member State, except that an offer to the public in that Member State |
|
| June 11, 2025 |
a06-finalformofdirectorr LIVANOVA PLC 2025 DIRECTOR INCENTIVE AWARD PLAN DIRECTOR RESTRICTED STOCK UNIT AWARD GRANT NOTICE LivaNova PLC, a public limited company incorporated under the laws of England and Wales (the “Company”), pursuant to its 2025 Director Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (“Holder”) the number of Restricted Stock Units (the “RSUs”) set forth below. |
|
| June 11, 2025 |
LivaNova PLC 2025 Director Incentive Award Plan final2025directorincenti LIVANOVA PLC 2025 DIRECTOR INCENTIVE AWARD PLAN (Adopted by the Board of Directors of LivaNova PLC on April 23, 2025, conditional on shareholder approval. |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 11, 2025 |
Second Amended and Restated LivaNova PLC 2022 Incentive Award Plan finalsecondamendedandres SECOND AMENDED AND RESTATED LIVANOVA PLC 2022 INCENTIVE AWARD PLAN (Adopted by the Board of Directors of LivaNova PLC on April 23, 2025, conditional on shareholder approval. |
|
| June 11, 2025 |
a03-finalsecondarrsuagre IMPORTANT NOTICES European Union/European Economic Area (“EU/EEA”) In relation to each Member State of the EEA, an offer to the public of any securities that comprise the RSUs (as defined below) (together “Securities”) which are the subject of the offer contemplated by this Grant Notice (as defined below) may not be made in that Member State, except that an offer to the pu |
|
| May 29, 2025 |
Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. exhibit1012025conflictmi Exhibit 1.01 LivaNova PLC Conflict Minerals Report for the Year Ended December 31, 2024 This Conflict Minerals Report (this “Report”) of LivaNova PLC has been prepared for the reporting period from January 1, 2024 to December 31, 2024, pursuant to Rule 13p-1 under the Securities Exchange Act of 1934 (the “Rule”). The Rule was adopted by the Securities and Exchange Commissi |
|
| May 29, 2025 |
As filed with the Securities and Exchange Commission on May 29, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37599 LivaNova |
|
| May 7, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 7, 2025 |
LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance EXHIBIT 99.1 NEWS RELEASE LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance –Delivered high-single-digit revenue growth, double-digit organic revenue growth, and continued operating margin expansion –Raised full-year 2025 revenue guidance; updated full-year 2025 guidance now incorporates impact of SNIA decision and currently applicable tariffs –Completed premarket approval submiss |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ De |
|
| April 30, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2025 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 25, 2025 |
1 April 2024 Ahmet Tezel Dear Ahmet, We are pleased to offer you employment with LivaNova USA Inc. |
|
| February 25, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 25, 2025 |
LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance London, February 25, 2025 – LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported fourth-quarter and full-year 2024 results and issued full-year 2025 guidance. Financial Summary and Highlights(1) •Fourth-quarter revenue of $321.8 million increased 3.8% on a |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37599 LivaNova PLC ( |
|
| February 25, 2025 |
LIVANOVA INSIDER TRADING POLICY 1 General Rules Capitalized terms have the meanings set out in Section 7 (“Definitions”). |
|
| February 25, 2025 |
LIVANOVA PLC Incentive Compensation Clawback Policy (As Adopted on 19 July 2023, Pursuant to Nasdaq Rule 5608) 1. |
|
| February 25, 2025 |
EXHIBIT 21.1 LIST OF SUBSIDIARIES LivaNova PLC and Subsidiaries As of December 31, 2024 Company Jurisdiction of Formation LivaNova Plc United Kingdom LivaNova Plc (Italian Branch) Italy Caisson Interventional, LLC USA CardiacAssist, Inc. Dba TandemLife USA Cyberonics Holdings, LLC USA Cyberonics Netherlands CV Netherlands ALung Technologies, LLC USA ImThera Medical, Inc. USA LivaNova Australia PTY |
|
| February 25, 2025 |
Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT LivaNova PLC (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are its ordinary shares, which have a nominal or par value of £1.00 each (the “ordinary shares”). The below is a summary of the applicable provisions |
|
| February 25, 2025 |
1 CONTRATTO DI LAVORO SUBORDINATO A TEMPO DETERMINATO FIXED TERM EMPLOYMENT CONTRACT TRA BETWEEN Sorin Group Italia S. |
|
| November 1, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2024 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37599 Liva |
|
| October 31, 2024 |
1 Without prejudice Subject to contract Trui Hebbelinck c/o 20 Eastbourne Terrace London, W2 6LG 6 September 2024 Dear Trui I am writing to you with the proposals of LivaNova PLC (the “Company”) in connection with the termination of your employment on agreed terms. |
|
| October 30, 2024 |
LivaNova Reports Third-Quarter 2024 Results EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Third-Quarter 2024 Results London, October 30, 2024 – LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended September 30, 2024 and raised full-year 2024 guidance. Financial Summary and Highlights(1) •Third-quarter revenue of $318.1 million increased 11.2% on both a reported and constant-curr |
|
| October 30, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2024 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| September 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37599 LivaNova |
|
| July 31, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| July 31, 2024 |
LivaNova Reports Second-Quarter 2024 Results EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Second-Quarter 2024 Results London, July 31, 2024 – LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended June 30, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance. Financial Summary and Highlights(1) •Second-quarter revenue of $318.6 million increased |
|
| June 13, 2024 |
filingfeetableforforms-8 Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) LivaNova PLC (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, £1. |
|
| June 13, 2024 |
As filed with the Securities and Exchange Commission on June 12, 2024. As filed with the Securities and Exchange Commission on June 12, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LivaNova PLC (Exact name of Registrant as specified in its charter) England and Wales 98-1268150 (State or other jurisdiction of incorporation or organization) (I.R.S. Em |
|
| June 12, 2024 |
Amendment No. 1 to the Amended and Restated LivaNova PLC 2022 Incentive Award Plan Amendment No. 1 to the Amended and Restated LivaNova PLC 2022 Incentive Award Plan WHEREAS, LivaNova PLC (the “Company”) maintains the Amended and Restated LivaNova PLC 2022 Incentive Award Plan (the “A&R 2022 Plan”); WHEREAS, pursuant to Section 12.1 of the A&R 2022 Plan, the board of directors of the Company (the “Board”) is authorized to amend the A&R 2022 Plan; WHEREAS, the Board has determine |
|
| June 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2024 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 12, 2024 |
Amendment No. 2 to the LivaNova PLC 2015 Incentive Award Plan Amendment No. 2 to the LivaNova PLC 2015 Incentive Award Plan WHEREAS, LivaNova PLC (the “Company”) maintains the LivaNova PLC 2015 Incentive Award Plan (as amended, the “2015 Plan”) for the purpose of granting equity awards to Non-Employee Directors (as defined in the 2015 Plan); WHEREAS, pursuant to Section 13.1 of the 2015 Plan, the board of directors of the Company (the “Board”) is authorized |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| May 31, 2024 |
Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. Exhibit 1.01 LivaNova PLC Conflict Minerals Report For the Year Ended December 31, 2023 This Conflict Minerals Report (this “Report”) of LivaNova PLC has been prepared for the reporting period from January 1, 2023 to December 31, 2023, pursuant to Rule 13p-1 under the Securities Exchange Act of 1934 (the “Rule”). The Rule was adopted by the Securities and Exchange Commission (“SEC”) to implement d |
|
| May 31, 2024 |
As filed with the Securities and Exchange Commission on May 30, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37599 LivaNova |
|
| May 3, 2024 |
EXECUTION VERSION 1st, February, 2024 Vladimir A. Makatsaria 124 Hudson Street, Apt 4A, New York, NY 10013, USA Dear Vladimir, We are pleased to offer you employment with LivaNova USA Inc. (the “Company”), a wholly owned subsidiary of LivaNova PLC (“LivaNova” and, together with its subsidiaries including the Company, the “LivaNova Group”), as the Chief Executive Officer of the LivaNova Group, comm |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 1, 2024 |
exhibit99-q12024changein Net Revenue (in thousands, unaudited) Three Months Ended March 31, 2023 Three Months Ended June 30, 2023 Six Months Ended June 30, 2023 Three Months Ended September 30, 2023 Nine Months Ended September 30, 2023 Three Months Ended December 31, 2023 Twelve Months Ended December 31, 2023 Cardiopulmonary United States $ 39,609 $ 50,001 $ 89,610 $ 52,281 $ 141,891 $ 60,467 $ 20 |
|
| May 1, 2024 |
LivaNova Reports First-Quarter 2024 Results EXHIBIT 99.1 NEWS RELEASE LivaNova Reports First-Quarter 2024 Results London, May 1, 2024 – LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance. Financial Summary and Highlights(1) •First-quarter revenue of $294.9 million increased 12. |
|
| April 26, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ De |
|
| April 17, 2024 |
LIVN / LivaNova PLC / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 LIVANOVA PLC (Name of Issuer) ORDINARY SHARES, PAR VALUE £1.00 PER SHARE (Title of Class of Securities) G5509L101 (CUSIP Number) APRIL 9, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2024 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 8, 2024 |
Form of Confirmation for Capped Call Transactions [Dealer’s name] [Dealer’s address]1 [], 2024 To: LivaNova PLC 20 Eastbourne Terrace London, United Kingdom, W2 6LG Attention: [] Telephone: [] E-mail: [] Re: [Base][Additional] Call Option Transaction The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between [DEALER] (“Dealer”) and LivaNova PLC (“Counterparty” or “Issuer”) as of the Trade Date specified below (the “Transaction”). |
|
| March 8, 2024 |
Execution Version LIVANOVA PLC, as Issuer, AND CITIBANK, N.A., as Trustee INDENTURE Dated as of March 8, 2024 2.50% Convertible Senior Notes due 2029 i #97987069v14 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01 . Definitions ............................................................................................................... 1 Section 1.02 . References to Interest ........... |
|
| March 8, 2024 |
Execution Version INCREMENTAL FACILITY AMENDMENT NO. 3 TO CREDIT AGREEMENT, dated as of March 8, 2024 (this “Incremental Amendment”), is made and entered into by and among LIVANOVA PLC, a company incorporated under the laws of England and Wales (“Holdings”), LIVANOVA USA, INC., a Delaware corporation (the “Borrower”), each of the entities listed under the caption “Third Incremental Amendment Revol |
|
| March 6, 2024 |
EXHIBIT 99.1 NEWS RELEASE LivaNova Announces Pricing of Private Offering of $300 Million of 2.50% Convertible Senior Notes Due 2029 London, March 5, 2024 — LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the pricing of $300 million aggregate principal amount of 2.50% convertible senior notes due 2029 (the “notes”) to be issued in a private offering only to |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 4, 2024 |
LivaNova Announces Proposed Private Offering of $300 Million of Convertible Senior Notes EXHIBIT 99.1 NEWS RELEASE LivaNova Announces Proposed Private Offering of $300 Million of Convertible Senior Notes London, March 4, 2024 — LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its intention to offer $300 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private offering only to persons reasonably believed |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| February 29, 2024 |
1 October 31, 2022 Michael Hutchinson Ridgewood, New Jersey Dear Mike, We are pleased to offer you employment with LivaNova USA Inc. |
|
| February 29, 2024 |
Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT LivaNova PLC (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are its ordinary shares, which have a nominal or par value of £1.00 each (the “ordinary shares”). The below is a summary of the applicable provisions |
|
| February 29, 2024 |
EXHIBIT 21.1 LIST OF SUBSIDIARIES LivaNova PLC and Subsidiaries As of December 31, 2023 Company Jurisdiction of Formation LivaNova Plc United Kingdom LivaNova Plc (Italian Branch) Italy Caisson Interventional, LLC USA CardiacAssist, Inc. Dba TandemLife USA Cyberonics Holdings, LLC USA Cyberonics Netherlands CV Netherlands ALung Technologies, Inc. USA ImThera Medical, Inc. USA LivaNova Australia PT |
|
| February 29, 2024 |
Compensation Recoupment Policy Policy # n/a Audience All Issue date: 19 July 2023 Approver Board of Directors Compensation Recoupment Policy 19 July 2023 LivaNova Compensation Recoupment Policy Introduction The LivaNova Plc (“LivaNova” or the “Company”) Board of Directors (“Board”) believes that the success of the Company for the benefit of its members as a whole requires it to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37599 LivaNova PLC ( |
|
| February 21, 2024 |
LivaNova Reports Fourth-Quarter and Full-Year 2023 Results EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Fourth-Quarter and Full-Year 2023 Results London, February 21, 2024 – LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter and full year ended December 31, 2023 and issued guidance for 2024. Financial Summary and Highlights1 •Fourth-quarter revenue of $310.1 million increased 12.8 percent on a re |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 12, 2024 |
LIVN / LivaNova PLC / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment SC 13G/A 1 livna621224.htm PRIMECAP MANAGEMENT CO/CA/ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* LivaNova PLC (Name of Issuer) COM (Title of Class of Securities) G5509L101 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designa |
|
| February 5, 2024 |
EXHIBIT 99.1 NEWS RELEASE LivaNova Announces Vladimir A. Makatsaria as CEO and Board Director William Kozy will remain Board Chair London, February 5, 2024 — LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its Board of Directors named Vladimir A. Makatsaria as the Company’s Chief Executive Officer (CEO) and a member of the Board of Directors, effective Mar |
|
| February 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2024 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| December 13, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2023 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 6, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 20, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2023 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 1, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 1, 2023 |
LivaNova Reports Third-Quarter 2023 Results EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Third-Quarter 2023 Results London, November 1, 2023 – LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended September 30, 2023 and raised full-year 2023 revenue and adjusted diluted earnings per share guidance. Financial Summary and Highlights1 •Third-quarter revenue of $286.1 million increa |
|
| November 1, 2023 | ||
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37599 Liva |
|
| October 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2023 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2023 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| September 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2023 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| September 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2023 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| July 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37599 LivaNova |
|
| July 26, 2023 |
LivaNova Reports Second-Quarter 2023 Results EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Second-Quarter 2023 Results London, July 26, 2023 – LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended June 30, 2023 and raised full-year 2023 guidance. Financial Summary and Highlights1 •Second-quarter revenue of $293.9 million increased 15.6% on a reported basis and increased 16.4% on a |
|
| July 26, 2023 |
As filed with the Securities and Exchange Commission on July 26, 2023. As filed with the Securities and Exchange Commission on July 26, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LivaNova PLC (Exact name of Registrant as specified in its charter) England and Wales 98-1268150 (State or other jurisdiction of incorporation or organization) (I.R.S. Em |
|
| July 26, 2023 |
executioncopyreleaseagre 1 Without prejudice Damien McDonald c/o 20 Eastbourne Terrace London W2 6LG 14 April 2023 Dear Damien I am writing to you with the proposals of LivaNova PLC (the "Company") in connection with the termination of your employment by reason of your resignation. |
|
| July 26, 2023 |
williamkozy04202023 |
|
| July 26, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2023 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| July 26, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) LivaNova PLC (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, £1. |
|
| June 16, 2023 |
AMENDED AND RESTATED LIVANOVA PLC 2022 INCENTIVE AWARD PLAN (Adopted by the Board of Directors of LivaNova PLC on April 19, 2023, conditional on shareholder approval. |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2023 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 31, 2023 |
Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. Exhibit 1.01 LivaNova PLC Conflict Minerals Report For the Year Ended December 31, 2022 This Conflict Minerals Report (this “Report”) of LivaNova PLC has been prepared for the reporting period from January 1, 2022 to December 31, 2022, pursuant to Rule 13p-1 under the Securities Exchange Act of 1934 (the “Rule”). The Rule was adopted by the Securities and Exchange Commission (“SEC”) to implement d |
|
| May 31, 2023 |
As filed with the Securities and Exchange Commission on May 31, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 9, 2023 |
LIVN / LivaNova PLC / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* LivaNova PLC (Name of Issuer) COM (Title of Class of Securities) G5509L101 (CUSIP Number) April 30, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] |
|
| May 3, 2023 |
finalpsudoubletriggeragr [AMACTIVE 4042992502] IMPORTANT NOTICES European Union/ European Economic Area (“EU/EEA”) In relation to each Member State of the EEA, an offer to the public of any securities that comprise the PSUs (as defined below) (together “Securities”) which are the subject of the offer contemplated by this Grant Notice (as defined below) may not be made in that Member State, except |
|
| May 3, 2023 |
LivaNova Reports First-Quarter 2023 Results EXHIBIT 99.1 NEWS RELEASE LivaNova Reports First-Quarter 2023 Results London, May 3, 2023 – LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2023 and raised full-year 2023 guidance. Financial Summary and Highlights1 •First-quarter revenue of $263.4 million increased 9.7 percent on a reported basis and in |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37599 LivaNova |
|
| May 3, 2023 |
finalsardoubletriggeragr [AMACTIVE 4042979934] IMPORTANT NOTICES European Union/ European Economic Area (“EU/EEA”) In relation to each Member State of the EEA, an offer to the public of any securities that comprise the SARs (as defined below) (together “Securities”) which are the subject of the offer contemplated by this Grant Notice (as defined below) may not be made in that Member State, except |
|
| May 3, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 3, 2023 |
finalrsudoubletriggeragr [AMACTIVE 4042992052] IMPORTANT NOTICES European Union/ European Economic Area (“EU/EEA”) In relation to each Member State of the EEA, an offer to the public of any securities that comprise the RSUs (as defined below) (together “Securities”) which are the subject of the offer contemplated by this Grant Notice (as defined below) may not be made in that Member State, except |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ De |
|
| April 28, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2023 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 14, 2023 |
LivaNova Board of Directors Announce Leadership Changes NEWS RELEASE LivaNova Board of Directors Announce Leadership Changes London, April 14, 2023 — LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced that Damien McDonald has resigned as Chief Executive Officer. |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2023 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 27, 2023 |
EXHIBIT 21.1 LIST OF SUBSIDIARIES LivaNova PLC and Subsidiaries As of December 31, 2022 Company Jurisdiction of Formation LivaNova Plc United Kingdom LivaNova Plc (Italian Branch) Italy Caisson Interventional, LLC USA CardiacAssist, Inc. Dba TandemLife USA Cyberonics Holdings, LLC USA Cyberonics Netherlands CV Netherlands ALung Technologies, Inc. USA ImThera Medical, Inc. USA LivaNova Australia PT |
|
| February 27, 2023 |
exhibit106 Exhibit 10.6 Stock Option Award Notification and Agreement Cyberonics, Inc. is committed to providing competitive compensation and benefits for its employees. Equity awards are one of the ways that we reward employees whose talent, commitment and exceptional performance help make us a strong and successful company. Thank you for your hard work and dedication to building a successful com |
|
| February 27, 2023 |
finalpsudoubletriggeragr [AMACTIVE 4042992502] IMPORTANT NOTICES European Union/ European Economic Area (“EU/EEA”) In relation to each Member State of the EEA, an offer to the public of any securities that comprise the PSUs (as defined below) (together “Securities”) which are the subject of the offer contemplated by this Grant Notice (as defined below) may not be made in that Member State, except |
|
| February 27, 2023 |
finalsardoubletriggeragr [AMACTIVE 4042979934] IMPORTANT NOTICES European Union/ European Economic Area (“EU/EEA”) In relation to each Member State of the EEA, an offer to the public of any securities that comprise the SARs (as defined below) (together “Securities”) which are the subject of the offer contemplated by this Grant Notice (as defined below) may not be made in that Member State, except |
|
| February 27, 2023 |
Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT LivaNova PLC (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are its ordinary shares, which have a nominal or par value of £1.00 each (the “ordinary shares”). The below is a summary of the applicable provisions |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37599 LivaNova PLC ( |
|
| February 27, 2023 |
finalrsudoubletriggeragr [AMACTIVE 4042992052] IMPORTANT NOTICES European Union/ European Economic Area (“EU/EEA”) In relation to each Member State of the EEA, an offer to the public of any securities that comprise the RSUs (as defined below) (together “Securities”) which are the subject of the offer contemplated by this Grant Notice (as defined below) may not be made in that Member State, except |
|
| February 27, 2023 |
letterdateddecember2022t Alex Shvartsburg Chief Financial Officer, LivaNova December 2022 Dear Alex, The Board of Directors of LivaNova (the “Board”) and I are pleased to inform you that effective January 1, 2023, your gross annual base salary will be increased to £430,000. |
|
| February 22, 2023 |
LivaNova Reports Fourth-Quarter and Full-Year 2022 Results EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Fourth-Quarter and Full-Year 2022 Results London, February 22, 2023 – LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full year ended December 31, 2022 and issued guidance for 2023. Fourth-Quarter Financial Summary and Highlights1 •Fourth-quarter revenue of $274.9 million |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2023 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 17, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2023 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 14, 2023 |
LIVN / LivaNova PLC / HARRIS ASSOCIATES L P Passive Investment SC 13G/A 1 formsc13ga-02142023090205.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* LivaNova PLC (Name of Issuer) Ordinary Shares - £1.00 par value per share (Title of Class of Securities) G5509L101 (CUSIP Number) December 31 , 2022 (Date of Event Which Requires Filing of this Statement) Check |
|
| February 9, 2023 |
LIVN / LivaNova PLC / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment SC 13G/A 1 livna420923.htm PRIMECAP MANAGEMENT CO/CA/ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* LivaNova PLC (Name of Issuer) COM (Title of Class of Securities) G5509L101 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designa |
|
| January 19, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2023 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 13, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 28, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2022 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 15, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 2, 2022 |
LivaNova Reports Third-Quarter 2022 Results EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Third-Quarter 2022 Results London, November 2, 2022 ? LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended September 30, 2022. Financial Summary and Highlights1 ?Revenue of $252.6 million for the quarter decreased 0.2 percent on a reported basis and increased 5.2 percent on a |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37599 Liva |
|
| November 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2022 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| September 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2022 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 29, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2022 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 3, 2022 |
AMENDMENT TO THE LIVANOVA PLC 2015 INCENTIVE AWARD PLAN WHEREAS, LivaNova PLC (the “Company”) maintains the LivaNova PLC 2015 Incentive Award Plan (the “2015 Plan”); WHEREAS, pursuant to Section 13. |
|
| August 3, 2022 |
IMPORTANT NOTICES European Union/ European Economic Area (“EU/EEA”) In relation to each Member State of the EEA, an offer to the public of any securities that comprise the PSUs (as defined below) (together “Securities”) which are the subject of the offer contemplated by this Grant Notice (as defined below) may not be made in that Member State, except that an offer to the public in that Member Stat |
|
| August 3, 2022 |
EXHIBIT E Amendment to Relevant 2020, 2021 and 2022 Restricted Stock Unit Awards under the LivaNova PLC 2015 Incentive Award Plan This amendment (the “Amendment”), dated as of June , 2022, hereby modifies each relevant 2020, 2021 and 2022 service-based restricted stock unit (“RSU”) award agreement evidencing a currently outstanding RSU award under the LivaNova PLC 2015 Incentive Award Plan (as permitted pursuant to Section 11. |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37599 LivaNova |
|
| August 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 3, 2022 |
WITHOUT PREJUDICE AND SUBJECT TO CONTRACT LIVANOVA PLC KEYNA SKEFFINGTON RETIREMENT AGREEMENT 1 THIS RETIREMENT AGREEMENT (the “Agreement”) is made on 2022 BETWEEN (1) LIVANOVA PLC, a company registered in England with registered number 09451374 and having its registered office at 20 Eastbourne Terrace, London, W2 6LG (the “Company”); and (2) KEYNA SKEFFINGTON, residing in London, England, United Kingdom (the “Executive”). |
|
| August 3, 2022 |
IMPORTANT NOTICES European Union/ European Economic Area (“EU/EEA”) In relation to each Member State of the EEA, an offer to the public of any securities that comprise the SARs (as defined below) (together “Securities”) which are the subject of the offer contemplated by this Grant Notice (as defined below) may not be made in that Member State, except that an offer to the public in that Member Stat |
|
| August 3, 2022 |
IMPORTANT NOTICES European Union/ European Economic Area (“EU/EEA”) In relation to each Member State of the EEA, an offer to the public of any securities that comprise the RSUs (as defined below) (together “Securities”) which are the subject of the offer contemplated by this Grant Notice (as defined below) may not be made in that Member State, except that an offer to the public in that Member Stat |
|
| August 3, 2022 |
EXHIBIT D Amendment to Outstanding 2021 and 2022 Performance Stock Unit Awards under the LivaNova PLC 2015 Incentive Award Plan This amendment (the “Amendment”), dated as of June , 2022, hereby modifies each 2021 and 2022 performance stock unit (“PSU”) award agreement evidencing a currently outstanding PSU award under the LivaNova PLC 2015 Incentive Award Plan (as permitted pursuant to Section 11. |
|
| August 3, 2022 |
LivaNova Reports Second-Quarter 2022 Results EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Second-Quarter 2022 Results London, August 3, 2022 – LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2022. Financial Summary and Highlights1 •Revenue of $254.2 million for the quarter, decreased 3.9 percent on a reported basis and increased 0.5 percent on a cons |
|
| July 6, 2022 |
Execution Version INCREMENTAL FACILITY AMENDMENT NO. 2 TO CREDIT AGREEMENT, dated as of July 6, 2022 (this ?Incremental Amendment?), is made and entered into by and among LIVANOVA PLC, a company incorporated under the laws of England and Wales (?Holdings?), LIVANOVA USA, INC.., a Delaware corporation (the ?Borrower?), each of the entities listed under the caption ?Second Incremental Amendment Term |
|
| July 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2022 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2022 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 13, 2022 |
LivaNova PLC 2022 Incentive Award Plan Exhibit 99.1 FINAL VERSION LIVANOVA PLC 2022 INCENTIVE AWARD PLAN (Adopted by the Board of Directors of LivaNova PLC on April 20, 2022 conditional on shareholder approval. Approved by the shareholders of LivaNova PLC on June 13, 2022.) Article 1. PURPOSE The purpose of the LivaNova PLC 2022 Incentive Award Plan (as it may be amended or restated from time to time, the ?Plan?) is to promote the succ |
|
| June 13, 2022 |
Calculation of Filing Fee Tables Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) LivaNova PLC (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, par value ?1. |
|
| June 13, 2022 |
As filed with the Securities and Exchange Commission on June 13, 2022. As filed with the Securities and Exchange Commission on June 13, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LivaNova PLC (Exact name of Registrant as specified in its charter) England and Wales 98-1268150 (State or other jurisdiction of incorporation or organization) (I.R.S. Em |
|
| May 27, 2022 |
Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD Exhibit 1.01 LivaNova PLC Conflict Minerals Report For the Year Ended December 31, 2021 This Conflict Minerals Report of LivaNova PLC (this ?Report?) has been prepared for the reporting period from January 1, 2021 to December 31, 2021 pursuant to Rule 13p-1 under the Securities Exchange Act of 1934 (the ?Rule?). The Rule was adopted by the Securities and Exchange Commission (?SEC?) to implement di |
|
| May 27, 2022 |
As filed with the Securities and Exchange Commission on May 27, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.????) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? De |
|
| May 4, 2022 |
LivaNova Reports First-Quarter 2022 Results EXHIBIT 99.1 NEWS RELEASE LivaNova Reports First-Quarter 2022 Results London, May 4, 2022 ? LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2022. Financial Summary and Highlights1 ?Worldwide sales were $240.2 million, a decrease of 3.0 percent on a reported basis and 0.3 percent on a constant-currency b |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 4, 2022 |
EXECUTION VERSION AMENDMENT NO. 2 TO CREDIT AGREEMENT, dated as of March 16, 2022 (the ?Amendment?), is made and entered into by and among LIVANOVA PLC, a company incorporated under the laws of England and Wales (?Holdings?), LIVANOVA USA, INC., a Delaware corporation (the ?Borrower?), the Lenders party hereto, and GOLDMAN SACHS BANK USA, as First Lien Administrative Agent (the ?First Lien Adminis |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37599 LivaNova |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.???????) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? |
|
| April 29, 2022 |
Registrant’s definitive proxy statement on Schedule 14A, filed with the Commission on April 29, 2022 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.????) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 21, 2022 |
Exhibit 10.2 To: Barclays Bank Ireland PLC Italy Branch Via della Moscova, 18 20121 - Milan Italy To the attention of: Mr Stefano Da Ros Via certified email (PEC): [email protected] Milan, 18th March 2022 Dear Sirs, Re: Pledge Agreement Following our conversations, we hereby propose to you to enter into a pledge agreement, to be executed by way of exchange of commercial correspondence, |
|
| March 21, 2022 |
Exhibit 10.1 To: Barclays Bank Ireland PLC Italy Branch Via della Moscova 18 20121 Milano Milan, 18/03/2022 Re: Letter of indemnity in respect of the issuance of Trade Finance guarantee by Barclays Bank Ireland PLC, Italy Branch ***** SUMMARY DOCUMENT Fees for issue of guarantee 0,50 % of the amount of the bank guarantee/bond per year, to be paid in advance on a quarterly basis Charges for issue ? |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2022 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 1, 2022 |
DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT LivaNova PLC (the ?Company?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), which are its ordinary shares, which have a nominal or par value of ?1.00 each (the ?ordinary shares?). The below is a summary of the applicable provisions |
|
| March 1, 2022 |
EXHIBIT 21.1 LIST OF SUBSIDIARIES LivaNova PLC and Subsidiaries As of December 31, 2021 Company Jurisdiction of Formation LivaNova Plc United Kingdom LivaNova Plc (Italian Branch) Italy Caisson Interventional, LLC USA CardiacAssist, Inc. Dba TandemLife USA Cyberonics Holdings, LLC USA Cyberonics Netherlands CV Netherlands Cyberonics Spain SL Spain ImThera Medical, Inc. USA LivaNova Australia PTY L |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37599 LivaNova PLC ( |
|
| March 1, 2022 |
EXECUTION VERSION INCREMENTAL FACILITY AMENDMENT NO. 1 TO CREDIT AGREEMENT, dated as of February 24, 2022 (this ?Incremental Amendment?), is made and entered into by and among LIVANOVA PLC, a company incorporated under the laws of England and Wales (?Holdings?), LIVANOVA USA, INC.., a Delaware corporation (the ?Borrower?), each of the entities listed under the caption ?Bridge Lenders? on the signa |
|
| February 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2022 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 23, 2022 |
LivaNova Reports Fourth-Quarter and Full-Year 2021 Results EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Fourth-Quarter and Full-Year 2021 Results London, February 23, 2022 ? LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full year ended December 31, 2021. For the fourth quarter of 2021, worldwide sales from continuing operations were $270.1 million, an increase of 0.2 perce |
|
| February 11, 2022 |
LIVN / LivaNova PLC / HARRIS ASSOCIATES L P Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* LIVANOVA PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) G5509L101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| February 10, 2022 |
LIVN / LivaNova PLC / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* LivaNova PLC (Name of Issuer) COM (Title of Class of Securities) G5509L101 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| December 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2021 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 12, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 3, 2021 |
LivaNova Reports Third Quarter 2021 Results EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Third Quarter 2021 Results London, November 3, 2021 ? LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended September 30, 2021. For the third quarter of 2021, worldwide sales from continuing operations were $253.2 million, an increase of 5.5 percent on a reported basis and 5.0 |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37599 Liva |
|
| August 16, 2021 |
EXHIBIT 99.1 NEWS RELEASE LivaNova Announces Early Retirement of $450 Million Term Loan and Executes $125 Million Revolving Credit Facility Announcement follows closing of underwritten offering of ordinary shares London, August 16, 2021 ? LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced the early retirement of its $450 million five-year senior |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 16, 2021 |
Exhibit 10.1 CREDIT AGREEMENT dated as of August 13, 2021 among LIVANOVA PLC, as Holdings, LIVANOVA USA INC., as the Borrower, the Lenders and Issuing Banks party hereto and GOLDMAN SACHS BANK USA, as First Lien Administrative Agent and First Lien Collateral Agent GOLDMAN SACHS BANK USA, BARCLAYS BANK PLC, and UBS SECURITIES LLC as Joint Lead Arrangers and Joint Bookrunners 32643.03100 TABLE OF CO |
|
| August 6, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2021 LivaNova PLC (Exact name of registrant as specified in charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 6, 2021 |
LivaNova Prices Offering of Ordinary Shares Exhibit 99.1 NEWS RELEASE LivaNova Prices Offering of Ordinary Shares London, August 3, 2021 ? LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced that it has priced an underwritten offering of 3,636,364 ordinary shares at a price to the public of $82.50 per share. The Company also granted the underwriters a 30-day option to acquire up to 545,454 |
|
| August 6, 2021 |
Exhibit 1.1 LivaNova PLC Ordinary Shares Underwriting Agreement August 3, 2021 Goldman Sachs & Co. LLC Barclays Capital Inc. UBS Securities LLC As representatives (the ?Representatives?) of the several Underwriters named in Schedule I hereto, c/o Goldman Sachs & Co. LLC, 200 West Street New York, New York 10282 c/o Barclays Capital Inc. 745 Seventh Avenue New York, New York 10019 c/o UBS Securitie |
|
| August 5, 2021 |
CALCULATION OF REGISTRATION FEE 424B2 1 tm2123363-4424b2.htm 424B2 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(2) Registration No. 333-258359 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Maximum aggregate offering price Amount of registration fee Ordinary shares, par value £1.00 $344,999,985(1) $37,639.50(2) (1) Assuming exercise in full of the underwriters’ over-allotment option. (2) Th |
|
| August 2, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2021 LivaNova PLC (Exact name of registrant as specified in charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 2, 2021 |
LivaNova Announces Offering of Ordinary Shares Exhibit 99.1 NEWS RELEASE LivaNova Announces Offering of Ordinary Shares London, August 2, 2021 ? LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it has commenced an underwritten offering of $300 million of its ordinary shares. LivaNova also intends to grant the underwriters of the offering a 30-day option to acquire up to an additional 15% o |
|
| August 2, 2021 |
As filed with the Securities and Exchange Commission on August 2, 2021 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 2, 2021 Registration No. |
|
| August 2, 2021 |
SUBJECT TO COMPLETION, DATED AUGUST 2, 2021 TABLE OF CONTENTS This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, as amended, but is not complete and may be changed. |
|
| July 28, 2021 |
LIVANOVA PLC ALEX SHVARTSBURG SERVICE AGREEMENT 1 THIS AGREEMENT is made on 23, July 2021 BETWEEN (1) LIVANOVA PLC, a company registered in England with registered number 09451374 and having its registered office at 20 Eastbourne Terrace, W2 6LG London (the ?Company?); and (2) ALEX SHVARTSBURG, residing 601 Balmoral Apartments, 2 Praed Street, W2 1AL London (the ?Executive?). |
|
| July 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37599 LivaNova |
|
| July 28, 2021 |
EX-99.1 2 a2q2021earningspressrelease.htm LIVANOVA PRESS RELEASE DATED JULY 28, 2021 EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Second Quarter 2021 Results and Appoints Alex Shvartsburg as Chief Financial Officer London, July 28, 2021 – LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2021. For the second |
|
| July 28, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2021 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 10, 2021 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2021 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 1, 2021 |
SD 1 livanova2020cmrreport.htm LIVANOVA FORM SD As filed with the Securities and Exchange Commission on June 1, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report LivaNova PLC England and Wales (State or other jurisdiction of incorporation or organization) 001-37599 (Commission File Number) 98-1268150 (I.R.S. Employer Identification N |
|
| June 1, 2021 |
Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form. Exhibit 1.01 LivaNova PLC Conflict Minerals Report For the Year Ended December 31, 2020 This Conflict Minerals Report of LivaNova PLC (this ?Report?) has been prepared for the reporting period from January 1, 2020 to December 31, 2020 pursuant to Rule 13p-1 under the Securities Exchange Act of 1934 (the ?Rule?). The Rule was adopted by the Securities and Exchange Commission (?SEC?) to implement di |
|
| June 1, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 1, 2021 |
EXHIBIT 99.1 NEWS RELEASE LivaNova Completes Initial Closing of Heart Valve Business to Gyrus Capital Additional local business closings to occur later this year London, June 1, 2021 ? LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it has successfully completed the initial closing of the divestiture of its heart valve (HV) business to Gyrus |
|
| April 30, 2021 |
Schedule 14A for our annual meeting of shareholders, filed on April 30, 2021 DEF 14A 1 tm2113973-1def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of t |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 28, 2021 |
LivaNova Reports First Quarter 2021 Results EXHIBIT 99.1 NEWS RELEASE LivaNova Reports First Quarter 2021 Results London, April 28, 2021 ? LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2021. For the first quarter of 2021, worldwide sales from continuing operations were $247.6 million, an increase of 2.1 percent on a reported basis and a decline |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37599 LivaNova |
|
| April 28, 2021 |
livn-20210331xex101 |
|
| April 28, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2021 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2021 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 15, 2021 |
EXHIBIT 2.1 DATED 9 APRIL 2021 LIVANOVA PLC and MITRAL HOLDCO S.? R.L. AMENDED AND RESTATED SHARE and ASSET PURCHASE AGREEMENT CONTENTS Page 1. Definitions and Interpretation 4 2. Sale and Purchase of the Transferred Shares; Sale and Purchase of the Local Businesses and Local Transferred Assets; Transfer of the Local Transferred Employees; Assumption of the Local Assumed Liabilities 5 3. Italian B |
|
| April 15, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2021 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 1, 2021 |
STATEMENT OF TERMS AND CONDITIONS OF EMPLOYMENT Exhibit 10.44 21st September 2017 Private & Confidential Alex Shvartsburg 18 Lancaster Gate London W2 3LH Dear Alex It is with great pleasure to outline below the offer of employment with LivaNova PLC. Position: Vice President Strategy and Innovation Start Date: 21st September 2017 The details of this offer and the terms of your contract of employment are further outlined in the accompanying Terms |
|
| March 1, 2021 |
LIVANOVA PLC ROY KHOURY SEPARATION AND SETTLEMENT AGREEMENT WITHOUT PREJUDICE AND SUBJECT TO CONTRACT Exhibit 10.47 LIVANOVA PLC ROY KHOURY SEPARATION AND SETTLEMENT AGREEMENT THIS SEPARATION AND SETTLEMENT AGREEMENT (the ?Agreement?) is made on February 2021 BETWEEN (1) LIVANOVA PLC, a company registered in England with registered number 09451374 and having its registered office at 20 Eastbourne Terrace, W2 6LG London (the ?Company?); and (2) ROY KHOURY, |
|
| March 1, 2021 |
EXHIBIT 21.1 LIST OF SUBSIDIARIES LivaNova PLC and Subsidiaries As of December 31, 2020 Company Jurisdiction of Formation LivaNova Plc United Kingdom LivaNova Plc (Italian Branch) Italy Caisson Interventional, LLC USA CardiacAssist, Inc. Dba TandemLife USA Corcym S.r.l. Italy Cyberonics Holdings, LLC USA Cyberonics Latam SRL Costa Rica Cyberonics Netherlands CV Netherlands Cyberonics Spain SL Spai |
|
| March 1, 2021 |
WITHOUT PREJUDICE AND SUBJECT TO CONTRACT Exhibit 10.41 LIVANOVA PLC THAD HUSTON SEPARATION AND SETTLEMENT AGREEMENT THIS SEPARATION AND SETTLEMENT AGREEMENT (the ?Agreement?) is made on 27, October 2020 BETWEEN (1) LIVANOVA PLC, a company registered in England with registered number 09451374 and having its registered office at 20 Eastbourne Terrace, W2 6LG London (the ?Company?); and (2) THAD HUS |
|
| March 1, 2021 |
Exhibit 10.46 October 2020 Alex Shvartsburg Dear Alex, I am pleased to inform you that effective from the earlier of 31 October 2020 and the date of the next 10Q filing for the Company, you will be covering the role of ad interim Chief Financial Officer. We have opened a search for the replacement of the former incumbent and you will maintain the role till the new Chief Financial Officer will star |
|
| March 1, 2021 |
Exhibit 10.45 Mr. ALEX SHVARTSBURG January 2019 Dear Alex, I am pleased to confirm that effective January 1st, 2019, your compensation package will be increased as follows: Annual Gross Base Salary: GP 235.000,00 Annual target bonus: 40% I would like to take this opportunity to thank you for your hard work and contribution to our business in 2018 and look forward to carrying on working together in |
|
| March 1, 2021 |
AMENDMENT no. 2 to CREDIT AGREEMENT Exhibit 10.49 AMENDMENT no. 2 to CREDIT AGREEMENT THIS AMENDMENT NO. 2 TO CREDIT AGREEMENT (this ?Agreement?) is entered into as of February 24, 2021 by and among LIVANOVA USA INC., a Delaware corporation (the ?Borrower?), LIVANOVA PLC, a company incorporated under the laws of England and Wales (?Holdings?), the Lenders party hereto and ARES CAPITAL CORPORATION, a Maryland Corporation, as administ |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37599 LivaNova PLC ( |
|
| March 1, 2021 |
Exhibit 10.43 PRIVATE AND CONFIDENTIAL [ Name ] LivaNova Plc 20 Eastbourne Terrace London W2 6LG [ Date ] Dear [ Name ], Letter of appointment The Board of Directors / Shareholders of LivaNova PLC (the ?Company?) on [ Date ] appointed / re-elected you as a member of the board of directors (the ?Board?). In addition, the Board [ appoined / ratified [ Position ] [Board / Committee ]. Your appointmen |
|
| March 1, 2021 |
Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT LivaNova PLC (the ?Company?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), which are its ordinary shares, which have a nominal or par value of ?1.00 each (the ?ordinary shares?). The below is a summary of the applicable provisions |
|
| March 1, 2021 |
CONFORMED COPY INCORPORATING AMENDMENT NO. 1 Exhibit 10.48 NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, THE LIEN AND SECURITY INTEREST GRANTED TO THE ADMINISTRATIVE AGENT PURSUANT TO THIS AGREEMENT AND THE EXERCISE OF ANY RIGHT OR REMEDY BY THE ADMINISTRATIVE AGENT HEREUNDER ARE SUBJECT TO THE PROVISIONS OF THE INTERCREDITOR AGREEMENT, DATED AS OF DECEMBER 30, 2020 (AS AMENDED, RESTATED, AMEND |
|
| March 1, 2021 |
LIVANOVA PLC 2015 INCENTIVE AWARD PLAN DIRECTOR RESTRICTED STOCK Unit AWARD Grant Notice Exhibit 10.42 LIVANOVA PLC 2015 INCENTIVE AWARD PLAN DIRECTOR RESTRICTED STOCK Unit AWARD Grant Notice LivaNova PLC, a public limited company incorporated under the laws of England and Wales (the ?Company?), pursuant to its 2015 Incentive Award Plan, as amended from time to time (the ?Plan?), hereby grants to the holder listed below (?Participant?) the number of Restricted Stock Units (the ?RSUs?) |
|
| February 25, 2021 |
EXHIBIT 10.1 AMENDMENT NO. 2 to CREDIT AGREEMENT THIS AMENDMENT NO. 2 TO CREDIT AGREEMENT (this ?Agreement?) is entered into as of February 24, 2021 by and among LIVANOVA USA INC., a Delaware corporation (the ?Borrower?), LIVANOVA PLC, a company incorporated under the laws of England and Wales (?Holdings?), the Lenders party hereto and ARES CAPITAL CORPORATION, a Maryland Corporation, as administr |
|
| February 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2021 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 24, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2021 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 24, 2021 |
LivaNova Reports Fourth Quarter and Full-Year 2020 Results EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Fourth Quarter and Full-Year 2020 Results London, February 24, 2021 ? LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2020. For the fourth quarter of 2020, worldwide sales from continuing operations were $269.6 million, a decrease of 6.3 percen |
|
| February 12, 2021 |
UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D. |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* LIVANOVA PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) G5509L101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| February 1, 2021 |
FOR SECTION 13 AND 16 REPORTING OBLIGATIONS liva20a1.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. G5509L101 13G Page 1 of 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* LivaNova PLC (Name of Issuer) Ordinary Shares - £1.00 par value per share (Title of Class of Securities) G5509L101 (CUSIP Number) December 31, 2020 (Date of Eve |
|
| December 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2020 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 7, 2020 |
LivaNova Announces Board Appointment and Board Leadership Changes Exhibit 99.1 NEWS RELEASE LivaNova Announces Board Appointment and Board Leadership Changes London, December 7, 2020 – LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced a series of enhancements to the Company’s governance. Todd Schermerhorn has been appointed to the Board of Directors, effective December 3. Schermerhorn has 35 years of experien |
|
| December 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2020 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 3, 2020 |
Asset Purchase Agreement, dated as of December 2, 2020, b Exhibit 2.1 DATED DECEMBER 2, 2020 LIVANOVA PLC and MITRAL HOLDCO S.À R.L. SHARE AND ASSET PURCHASE AGREEMENT CONTENTS Page 1. Definitions and Interpretation 4 2. Sale and Purchase of the Transferred Shares; Sale and Purchase of the Local Businesses and Local Transferred Assets; Transfer of the Local Transferred Employees; Assumption of the Local Assumed Liabilities 4 3. Italian Business Carve-Out |
|
| December 3, 2020 |
LivaNova and Gyrus Capital Enter into Agreement for the Purchase of Heart Valve Business EXHIBIT 99.1 NEWS RELEASE LivaNova and Gyrus Capital Enter into Agreement for the Purchase of Heart Valve Business London, December 3, 2020 – LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, and Gyrus Capital (Gyrus), an investment firm dedicated to investments in the healthcare and sustainability sectors, today announced they have entered into an agreement w |
|
| October 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2020 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 29, 2020 |
LIVANOVA PLC 2015 INCENTIVE AWARD SUB-PLAN PERFORMANCE STOCK UNIT AWARD GRANT NOTICE EXHIBIT 10.2 LIVANOVA PLC 2015 INCENTIVE AWARD SUB-PLAN PERFORMANCE STOCK UNIT AWARD GRANT NOTICE LivaNova PLC, a public limited company incorporated under the laws of England and Wales (the “Company”), pursuant to its 2015 Incentive Award Plan (including where relevant the Sub-Plan for UK Participants and/or the Sub-Plan for France), as amended from time to time (the “Sub-Plan”), hereby grants to |
|
| October 29, 2020 |
EXHIBIT 10.3 LIVANOVA PLC 2015 INCENTIVE AWARD SUB-PLAN STOCK APPRECIATION RIGHT GRANT NOTICE AND STOCK APPRECIATION RIGHT AGREEMENT LivaNova PLC, a public limited company incorporated under the laws of England and Wales (the “Company”), pursuant to its 2015 Incentive Award Plan (including where relevant the Sub-Plan for UK Participants), as amended from time to time (the “Sub-Plan”), hereby grant |
|
| October 29, 2020 |
LivaNova Reports Third Quarter 2020 Results Company announces Chief Financial Officer transition NEWS RELEASE LivaNova Reports Third Quarter 2020 Results Company announces Chief Financial Officer transition London, October 29, 2020 – LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended September 30, 2020. |
|
| October 29, 2020 |
LIVANOVA PLC 2015 INCENTIVE AWARD SUB-PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE EXHIBIT 10.1 LIVANOVA PLC 2015 INCENTIVE AWARD SUB-PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE LivaNova PLC, a public limited company incorporated under the laws of England and Wales (the “Company”), pursuant to its 2015 Incentive Award Plan (including where relevant the Sub-Plan for UK Participants and/or the Sub-Plan for France), as amended from time to time (the “Sub-Plan”), hereby grants to |
|
| October 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37599 Liva |
|
| August 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2020 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| July 29, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2020 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| July 29, 2020 |
Exhibit 10.10 Amendment to Outstanding 2019 and 2020 Restricted Stock Unit Awards under the LivaNova PLC 2015 Incentive Award Plan This amendment (the “Amendment”), dated as of June 15, 2020, hereby modifies each 2019 and 2020 service-based restricted stock unit (“RSU”) award agreement evidencing a currently outstanding RSU award under the LivaNova PLC 2015 Incentive Award Plan (as permitted pursu |
|
| July 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37599 LivaNova |
|
| July 29, 2020 |
Exhibit 10.1 December 2019 Dear Roy Khoury, We are happy to confirm your new role as President International Commercial and SVP Global Strategic Marketing. Effective January 1, 2020, your gross annual base salary is GBP 305,000 and your target variable compensation will be 65% of the weighted average of your annual base salary during the year. In addition, we can confirm that, on March 2020, we wi |
|
| July 29, 2020 |
Exhibit 10.11 Amendment to Outstanding 2018 Restricted Stock Unit Awards under the LivaNova PLC 2015 Incentive Award Plan This amendment (the “Amendment”), dated as of June 15, 2020, hereby modifies each 2018 service-based restricted stock unit (“RSU”) award agreement evidencing a currently outstanding RSU award under the LivaNova PLC 2015 Incentive Award Plan (as permitted pursuant to Section 11. |
|
| July 29, 2020 |
Exhibit 10.12 Amendment to Outstanding 2018, 2019 and 2020 Performance Stock Unit Awards under the LivaNova PLC 2015 Incentive Award Plan This amendment (the “Amendment”), dated as of June 15, 2020, hereby modifies each 2018, 2019 and 2020 performance stock unit (“PSU”) award agreement evidencing a currently outstanding PSU award under the LivaNova PLC 2015 Incentive Award Plan (as permitted pursu |
|
| July 29, 2020 |
LivaNova Reports Second Quarter 2020 Results EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Second Quarter 2020 Results London, July 29, 2020 – LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2020. For the second quarter of 2020, worldwide sales from continuing operations were $182.2 million, a decrease of 34.3 percent on a reported basis and a decline |
|
| July 29, 2020 |
Exhibit 10.2 December 2019 Dear Marco Dolci, We are happy to confirm your new role as SVP Global Operations & Global Research and Development. Effective January 1, 2020, your gross annual base salary is Euro 500,000 and your target variable compensation will be 60% of the weighted average of your annual base salary during the year. In addition, we can confirm that, on March 2020, we will recommend |
|
| July 29, 2020 |
EXHIBIT 3.1 ARTICLES OF ASSOCIATION of LIVANOVA PLC PUBLIC LIMITED COMPANY the “Company” (effective as from 29 June 2020) ARTICLES OF ASSOCIATION CONTENTS Clause Page 1. MODEL ARTICLES NOT TO APPLY 1 2. INTERPRETATION 1 3. LIABILITY OF MEMBERS 4 4. SHARES AND SHARE CAPITAL 4 5. AUTHORITY TO ALLOT SHARES AND DISAPPLICATION OF PRE-EMPTION RIGHTS 6 6. VARIATION OF RIGHTS 7 7. SHARE CERTIFICATES 8 8. |
|
| June 30, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2020 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2020 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 17, 2020 |
EX-4.1 Exhibit 4.1 LIVANOVA USA, INC., as Issuer LIVANOVA PLC, as Guarantor AND CITIBANK, N.A., as Trustee INDENTURE Dated as of June 17, 2020 3.00% Cash Exchangeable Senior Notes due 2025 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS Section 1.01 Definitions 1 Section 1.02 References to Interest 13 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES Section 2.01 Designation |
|
| June 17, 2020 |
Form of Capped Call Confirmation. EX-10.1 Exhibit 10.1 [Dealer name] [Address] [ ], 2020 To: LivaNova USA, Inc. c/o LivaNova PLC 20 Eastbourne Terrace London, United Kingdom, W2 6LG Attention: [ ] Telephone No.: [ ] Re: Call Option Transaction The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between [Dealer name] (“Dealer”)[, through its a |
|
| June 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
